Cited by 2,302PARP inhibition in cancer therapyPancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Open access

Golan, Talia, Hammel, Pascal, Reni, Michele, Van Cutsem, Eric, Macarulla, Teresa, Hall, Michael J., Park, Joon-Oh, Hochhauser, Daniel, Arnold, Dirk, Oh, Do-Youn, Reinacher-Schick, Anke, Tortora, Giampaolo, Algül, Hana, O’Reilly, Eileen M., McGuinness, David, Cui, Karen Y., Schlienger, Katia, Locker, Gershon Y., Kindler, Hedy L.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1903387PMC PMC6810605

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1903387

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citation
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citation
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269

Show all 24 references

Sorted by citations

Items 901–1,000 of 1,002

Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?
Kokkinos, J., Jensen, A., Sharbeen, G., McCarroll, J. A., Goldstein, D., Haghighi, K. S., & Phillips, P. A. (2021) · Cancers · doi:10.3390/cancers13102427 · Cited by 14
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue
Wright, A. A., Poort, H., Tavormina, A., Schmiege, S. J., Matulonis, U. A., Campos, S. M., Liu, J. F., Slivjak, E. T., Gilmour, A. L., Salinger, J. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.020 · Cited by 12
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
Gong, Z., Yang, Y., Zhang, J., & Guo, W. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0351 · Cited by 12
Pathology and Molecular Characteristics of Pancreatic Cancer
Kearney, J. F., Adsay, V. N., & Yeh, J. J. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.003 · Cited by 15
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer
Yu, K. H., Park, J., Mittal, A., Abou‐Alfa, G. K., Dika, I. E., Epstein, A. S., Ilson, D. H., Kelsen, D. P., Ku, G. Y., Li, J., et al. (2022) · Cancer · doi:10.1002/cncr.34269 · Cited by 12
Self-citation
Systemic oncological treatments in patients with advanced pancreatic cancer: a scoping review and evidence map
Salazar, J., Bracchiglione, J., Acosta‐Dighero, R., Meza, N., Meade, A.-G., Quintana, M. J., Requeijo, C., Rodríguez-Grijalva, G., Santero, M., Selva, A., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-022-07564-8 · Cited by 12
Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
Sun, W., Wu, Y., Ma, F., Fan, J., & Qiao, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041588 · Cited by 12
Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile
Hijioka, S., Nagashio, Y., Maruki, Y., Kawasaki, Y., Takeshita, K., Morizane, C., & Okusaka, T. (2023) · Diagnostics · doi:10.3390/diagnostics13071275 · Cited by 12
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
Kumar, P. A., Serinelli, S., Zaccarini, D. J., Huang, R. S. P., Danziger, N. A., Janovitz, T., Basnet, A., Sivapiragasam, A., Graziano, S. L., & Ross, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169586 · Cited by 13
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Beatty, G. L., Delman, D., Yu, J., Liu, M., Li, J. H., Zhang, L., Lee, J. W., Chang, R. B., Bahary, N., Kennedy, E. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0535 · Cited by 13
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)
Overbeek, J. K., Guchelaar, N. A. D., Ali, M. I. M., Ottevanger, P. B., Bloemendal, H. J., Koolen, S. L. W., Mathijssen, R. H. J., Boere, I. A., Hamberg, P., Huitema, A. D. R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113346 · Cited by 14
Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
Chen, H., Hu, Y., Zhuang, Z., Wang, D., Ye, Z., Ji, J., & Cheng, X. (2023) · Cancers · doi:10.3390/cancers15215114 · Cited by 12
Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications
Laguna, J. C., Pastor, B., Nalda, I., Hijazo‐Pechero, S., Teixidó, C., Potrony, M., Puig‐Butillé, J. A., & Mezquita, L. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02607-9 · Cited by 13
Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC)
Jacobs, M. F., & Stoffel, E. M. (2024) · Familial Cancer · doi:10.1007/s10689-024-00372-5 · Cited by 15
PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma
Mohan, A., Quingalahua, E. C., Gunchick, V., Paul, S., Kumar‐Sinha, C., Crysler, O., Zalupski, M. M., & Sahai, V. (2024) · The Oncologist · doi:10.1093/oncolo/oyae163 · Cited by 12
Current status and prospect of the DNA double-strand break repair pathway in colorectal cancer development and treatment
Yang, K., Zhu, L., Liu, C. X., Zhou, D., Zhu, Z., Xu, N., & Li, W. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167438 · Cited by 13
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Hoang, T. A., & Tsang, E. S. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01149-w · Cited by 15
Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers
Matsubayashi, H., Kiyozumi, Y., Ishiwatari, H., Uesaka, K., Kikuyama, M., & Ono, H. (2019) · Diagnostics · doi:10.3390/diagnostics9040169 · Cited by 12
Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer
Tanaka, E., Uchida, D., Shiraha, H., Kato, H., Ohyama, A., Iwamuro, M., Watanabe, M., Kumon, H., & Okada, H. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200309125709 · Cited by 12
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer
Willenbrock, F. W., Cox, C., Parkes, E. E., Wilhelm-Benartzi, C. S., Abraham, A., Owens, R., Sabbagh, A. A., Jones, C. M., Hughes, D. L. I., Maughan, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01120-z · Cited by 12
Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials
Zhang, Z., Song, J., Xie, C., Pan, J., Lu, W., & Liu, M. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00556-2 · Cited by 12
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies
Mehta, R. J., Wood, A. C., Yu, J. B., & Kim, R. D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1898586 · Cited by 12
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
Palleschi, M., Tedaldi, G., Sirico, M., Virga, A., Ulivi, P., & Giorgi, U. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157884 · Cited by 13
BRCA mutations in pancreatic cancer and progress in their targeting
Alkassis, S., Yazdanpanah, O., & Philip, P. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1957462 · Cited by 13
Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report
Wu, C., Fan, M., & Hu, Y. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001160 · Cited by 12
Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer
Lundy, J., Gao, H., Berry, W., Moghaddam, S. M., Jenkins, B. J., & Croagh, D. G. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1107 · Cited by 12
Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion
Guo, N., Li, M., Wang, L., Chen, H., Song, S., Miao, Z., & He, J. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2024414 · Cited by 14
Genetic medicine is accelerating in Japan
Hayashi, S., Kubo, M., Kaneshiro, K., Kai, M., Yamada, M., Morisaki, T., Takao, Y., Shimazaki, A., Shikada, S., & Nakamura, M. (2022) · Breast Cancer · doi:10.1007/s12282-022-01342-4 · Cited by 13
Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values
Amin, S., Joo, S., Nolte, S., Yoo, H. K., Patel, N. R., Byrnes, H. F., Costa-Cabral, S., & Johnson, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09661-7 · Cited by 12
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects
Hasanov, E., Pimentel, I., Cruellas, M., Lewis, M. A., Jonasch, E. W., & Balmañà, J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350232 · Cited by 12
Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL
Moser, R. D., Annis, J. E., Nikolova, O. H., Whatcott, C., Gurley, K. E., Méndez, E., Moran‐Jones, K., Dorrell, C., Sears, R. C., Kuo, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4222 · Cited by 12
Management of Metastatic Pancreatic Cancer—Comparison of Global Guidelines over the Last 5 Years
Pajewska, M., Partyka, O., Czerw, A. I., Deptała, A., Cipora, E., Gąska, I., Wojtaszek, M., Sygit, K., Sygit, M., Krzych‐Fałta, E., et al. (2023) · Cancers · doi:10.3390/cancers15174400 · Cited by 12
Epigenetic silencing of BEND4, a novel DNA damage repair gene, is a synthetic lethal marker for ATM inhibitor in pancreatic cancer
Yao, Y., Lv, H., Zhang, M., Li, Y., Herman, J. G., Brock, M. V., Gao, A., Wang, Q., Fuks, F., Zhang, L., et al. (2024) · Frontiers of Medicine · doi:10.1007/s11684-023-1053-3 · Cited by 12
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies
Li, Y., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312113011 · Cited by 12
Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma
Hu, H., Zhu, Y., Pu, N., Burkhart, R. A., Burns, W. R., Laheru, D. A., Zheng, L., He, J. P., Goggins, M., & Yu, J. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.06.019 · Cited by 12
Contemporary management of pancreas cancer in older people
Baltatzis, M., Rodriquenz, M. G., Siriwardena, A. K., & Carino, N. D. L. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.08.007 · Cited by 12
Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC
Dujardin, P., Baginska, A. K., Urban, S., & Grüner, B. M. (2021) · Cancers · doi:10.3390/cancers13164187 · Cited by 12
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Umemoto, K., & Sunakawa, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103465 · Cited by 12
Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
Pan, J. G., Ye, D., & Zhu, Y. (2022) · Prostate International · doi:10.1016/j.prnil.2022.04.005 · Cited by 12
The current state of molecular profiling in gastrointestinal malignancies
Mukherji, R., Yin, C., Hameed, R., Alqahtani, A. J., Kulasekaran, M., He, A. R., Weinberg, B. A., Marshall, J. L., Hartley, M. L., & Noel, M. S. (2022) · Biology Direct · doi:10.1186/s13062-022-00322-0 · Cited by 13
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment
Catalano, M., Iannone, L. F., Cosso, F., Generali, D., Mini, E., & Roviello, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2158813 · Cited by 13
Pancreatic Cancer: Epidemiology, Risk Factors, and Prevention
Mack, S., Koessler, T., Bichard, P., & Frossard, J. (2025) · Onco · doi:10.3390/onco5030037 · Cited by 15
Lactylation-driven nuclear RIG-I promoted by lactate transporter inhibitor suppresses DNA damage repair through inhibiting PARP1 activity
Li, Y., Wang, C., Zhou, S., Shi, Y., Zhu, D., & Zheng, X. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116854 · Cited by 11
The Achilles’ Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials
Siolas, D., Morrissey, C., & Oberstein, P. E. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000052 · Cited by 11
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
Roosan, M. R., Mambetsariev, I., Pharaon, R. R., Fricke, J., Baroz, A. R., Chao, J., Chen, C., Nasser, M. W., Chirravuri‐Venkata, R., Jain, M., et al. (2021) · Cancers · doi:10.3390/cancers13112776 · Cited by 11
Comparison of Adverse Reactions Caused by Olaparib for Different Indications
Zhou, Y., Zhao, S., Wu, T., & Zhang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.968163 · Cited by 11
Health Disparities in Presentation, Treatment, Genomic Testing, and Outcomes of Pancreatic Cancer in Hispanic and Non-Hispanic Patients
Halder, R., Veeravelli, S., Cheng, C., Estrada-Mendizábal, R. J., & Recio‐Boiles, A. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01486-1 · Cited by 11
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models
Karmokar, A., Sargeant, R., Hughes, A. M., Baakza, H., Wilson, Z., Talbot, S., Bloomfield, S., Leo, E., Jones, G. N., Likhatcheva, M., et al. (2023) · Cancers · doi:10.3390/cancers15164195 · Cited by 11
Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review
Tan, H., & Hosein, P. J. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-85 · Cited by 11
Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project
Shimoyama, R., Imamura, Y., Uryu, K., Mase, T., Fujimura, Y., Hayashi, M., Ohtaki, M., Ohtani, K., Shinozaki, N., & Minami, H. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2694 · Cited by 11
Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas
Jiang, Y., Wu, Y., Zhang, L., Wang, Y., Xu, G., Deng, Y., Han, L., Li, E., Ma, Q., Xu, M., et al. (2023) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbad030 · Cited by 11
ADP-ribosylation: An emerging direction for disease treatment
Liu, Y., Che, Y., Qiu, H.-L., Xia, H., Feng, Y.-Z., Deng, J.-Y., Yuan, Y., & Tang, Q. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102176 · Cited by 13
Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology
Morales, M. G., Visa, L., Vázquez, E., Feliú, J., Shahi, P. K., Sáez, B. L., Hernández, B. L. D. S. V., Macarulla, T. M., & Sarrió, R. G. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03386-8 · Cited by 11
Self-citation
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
Rimini, M., Loi, E., Rizzato, M. D., Pressiani, T., Vivaldi, C., Gusmaroli, E., Antonuzzo, L., Martinelli, E., Garajová, I., Giordano, G., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01032-5 · Cited by 12
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Nguyen, L. L., Watson, Z. L., Ortega, R., Woodruff, E. R., Jordan, K. R., Iwanaga, R., Yamamoto, T. M., Bailey, C. A., To, F., Jeong, A. D., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0613 · Cited by 11
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Safyan, R. A., Kim, E., Dekker, E. N., Homs, M. Y. V., Aguirre, A. J., Koerkamp, B. G., & Chiorean, E. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438598 · Cited by 12
Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma
Labiano, I., Huerta, A. E., Alsina, M., Arasanz, H., Castro, N., Mendaza, S., Lecumberri, A., González‐Borja, I., Guerrero‐Setas, D., Patiño‐García, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67235-y · Cited by 13
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
Piha-Paul, S. A., Tseng, C., Leung, C. H., Yuan, Y., Karp, D. D., Subbiah, V., Hong, D. S., Fu, S., Naing, A., Rodon, J. A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00634-6 · Cited by 11
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
M'Baloula, J., Tougeron, D., Boilève, A., Jeanbert, E., Guimbaud, R., Abdelghani, M. B., Durand, A., Turpin, A., Quesada, S., Blanc, J. F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115051 · Cited by 11
Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis
Jin, W., Yang, Q. K., Zhang, Z., & Li, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03771-w · Cited by 12
STK39-mediated amplification of γ-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance
Xu, Y., Li, C., Yin, H., Nowsheen, S., Xu, X., Kang, W., Liu, X., Chen, L., Lou, Z., Yi, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1099 · Cited by 11
Prospects for PARG inhibitors in cancer therapy
Hu, Y., Meng, Y., Zhuang, Z., Li, Y., Nan, J., Xu, N., Ye, Z., & Ji, J. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae050 · Cited by 12
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, C., Armstrong, A. J., Shore, N. D., George, D. J., Oya, M., Sugimoto, M., McKay, R. R., Hussain, M., & Clarke, N. W. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01146-4 · Cited by 15
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer
Jiang, B., Shang, Y., Zhang, X., He, W., Hua, H., Ye, F., Zhou, X., Li, Y., Zhong, W., Jiang, W., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf141 · Cited by 12
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Merz, V., Cavaliere, A., Messina, C. G. M., Salati, M., Zecchetto, C., Casalino, S., Milella, M., Caffo, O., & Melisi, D. (2020) · Cancers · doi:10.3390/cancers12051131 · Cited by 11
Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma
Bustamante, B., Sinha, R., Rice, B., Nizam, A., Shan, W., Goldberg, G. L., John, V. S., Lin, D. I., Danziger, N. A., Pavlick, D. C., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00393 · Cited by 11
Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
Stoll, S., Unger, S., Azzarello-Burri, S. M., Chappuis, P. O., Graffeo, R., Pichert, G., Röthlisberger, B., Taban, F., & Riniker, S. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30038 · Cited by 11
Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients
Schlick, K., Kiem, D., Huemer, F., Neureiter, D., Weiß, L., & Greil, R. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211042139 · Cited by 11
Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach
Winer, A., & Dotan, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00892-7 · Cited by 11
Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003
Kim, T. W., Taı̈eb, J., Gurary, E. B., Lerman, N., Cui, K. Y., & Yoshino, T. (2021) · Future Oncology · doi:10.2217/fon-2021-0899 · Cited by 11
Self-citation
Systemic immune changes accompany combination treatment with immunotoxin LMB ‐100 and nab‐paclitaxel
Pegna, G. J., Lee, M., Peer, C. J., Ahmad, M. I., Venzon, D. J., Yu, Y., Yuno, A., Steinberg, S. M., Cao, L., Figg, W. D., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5290 · Cited by 11
A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
McLean, B. J., Istadi, A., Clack, T., Vankan, M., Schramek, D., Neely, G. G., & Pajic, M. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200014 · Cited by 12
Differences in DNA damage repair gene mutations between left‐ and right‐sided colorectal cancer
Huang, W., Li, W., Xu, N., Li, H., Zhang, Z., Zhang, X., He, T., Yao, J., Xu, M., He, Q., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5716 · Cited by 11
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
Sarfraz, H. R., Saha, A., Jhaveri, K. S., & Kim, D. W. (2023) · Current Oncology · doi:10.3390/curroncol30060404 · Cited by 11
Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic Development
Yap, T. A., Stadler, Z. K., Stout, L. A., & Schneider, B. P. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390738 · Cited by 11
Comparison of core needle biopsy and fine-needle aspiration methods in CT-guided percutaneous sampling of pancreatic tumors
Liu, J., Huang, W., Wang, S., Wu, Z., Ziyin, W., Ding, X., & Wang, Z. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1290_22 · Cited by 11
Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products
Park, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115906 · Cited by 13
ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma
Liu, Y., Cao, Y., Liu, P., Zhai, S., Liu, Y., Tang, X., Lin, J., Shi, M., Qi, D., Deng, X., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00907-5 · Cited by 12
Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancer
Sishc, B. J., Saha, J., Alves, E. M., Ding, L., Lu, H., Wang, S.-Y., Swancutt, K. L., Nicholson, J. H., Facoetti, A., Pompoš, A., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00800-4 · Cited by 10
Risk Assessment and Genetic Testing for Inherited Gastrointestinal Syndromes.
Stoll, J., & Kupfer, S. S. (2019) · PubMed Central · Cited by 11
Targeted therapy for pancreatic cancer: lessons learned and future opportunities
Thomas, A. G., & Awasthi, N. (2021) · Digestive Medicine Research · doi:10.21037/dmr-21-21 · Cited by 11
High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis
Thakur, N., Yim, K., Abdul‐Ghafar, J., Seo, K. J., & Chong, Y. (2021) · Cancers · doi:10.3390/cancers13225594 · Cited by 11
Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next‐generation sequencing
Jiang, H., Huang, F., Chen, X., Zhang, L., Shen, M., Pan, B., Wang, B., & Guo, W. (2023) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2170 · Cited by 11
Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant
Sunami, T., Yamada, A., Kondo, T., Kanai, M., Nagai, K., Uchida, Y., Yokode, M., Matsumori, T., Uza, N., Murakami, H., et al. (2022) · Pancreas · doi:10.1097/mpa.0000000000002150 · Cited by 11
Familial Pancreatic Cancer
Klein, A. P. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch124 · Cited by 11
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 13
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 14
Two decades of PARP inhibitor synthetic lethality in cancer
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2026) · Nature · doi:10.1038/s41586-026-10404-y · Cited by 10
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
Ramaswamy, A., Srinivas, S., Chaudhari, V. A., BHARGAVA, P. G., BHANDARE, M. S., Shrikhande, S. V., & Ostwal, V. S. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1367 · Cited by 10
Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report
Yuan, F., Liu, N., Yang, M., Zhang, X., Luo, H., & Zhou, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i11.3461 · Cited by 10
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Su, Y., Chiang, N., Chiu, T., Huang, C., Hsu, S., Lin, H., Yang, S., Yang, Y., Chou, W., Chen, Y., et al. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100696 · Cited by 11
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases
Desai, A. P., Pasquina, L. W., Nulsen, C., Keller-Evans, R. B., Mata, D. A., Tukachinsky, H., & Oxnard, G. R. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100140 · Cited by 10
The efficacy of bile liquid biopsy in the diagnosis and treatment of biliary tract cancer
Miura, Y., Ohyama, H., Mikata, R., Hirotsu, Y., Amemiya, K., Mochizuki, H., Ikeda, J., Ohtsuka, M., Kato, N., & Omata, M. (2024) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1432 · Cited by 11
Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma − Heading towards a promising change in treatment paradigm
Mahmood, U., Carrier, E., & Khan, K. H. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102750 · Cited by 10
PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience
Miao, R., Blue, K., Sommerer, K. R., Shah, A., Bottiglieri, S., Cueto, A. D., Berry, D. K., Ho, T. T., Hicks, J. K., & Kim, D. W. (2024) · Cancers · doi:10.3390/cancers16203447 · Cited by 12
Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review)
Luan, X., Wang, X., Bian, G., Li, X., Gao, Z., Liu, Z., Zhang, Z., Han, T., Zhao, J., Zhao, H., et al. (2024) · Oncology Reports · doi:10.3892/or.2024.8846 · Cited by 10
Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials
Shenoy, A., Yousif, A., & Hussain, M. D. (2025) · Cancers · doi:10.3390/cancers17081319 · Cited by 10
Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma
Herbert, K. J., Upstill‐Goddard, R., Dreyer, S. B., Rebus, S., Initiative, A. P. C. G., Pilarsky, C. P., Mukhopadhyay, D., Lord, C. J., Genomics Innovation Alliance, Biankin, A. V., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03051-z · Cited by 11
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Nouruzi, S., Kobelev, M., Tabrizian, N., Gleave, M. E., & Zoubeidi, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00282-8 · Cited by 13

Authors: Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
Affiliations: Tel Aviv University (IL)
From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
ORCID: Golan, Talia
Hammel, Pascal
Reni, Michele
Macarulla, Teresa
Hall, Michael J.
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Tortora, Giampaolo
Algül, Hana
McGuinness, David
Cui, Karen Y.
Locker, Gershon Y.
Kindler, Hedy L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-07-25
Volume: 381
Issue: 4
Pages: 317-327
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1903387
PMC: PMC6810605
OpenAlex: W2947826965
Cited by: 2,302
References: 24
Citations by year: 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
FWCI: 129.05
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Lirias (submittedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: AstraZeneca (NA)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
MeSH terms: Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks